Skip to main content
SpringerLink
Log in

Incidence, Survival Outcome, and Prognostic Nomogram of Patients with Angioimmunoblastic T-cell Lymphoma: a Population-based Analysis

  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

Due to the rarity of angioimmunoblastic T-cell lymphoma (AITL), very limited data concerning its incidence patterns and prognostic factors are available. This study aimed to explore the incidence, characteristics, survival outcomes, and prognostic factors of AITL.

Methods

Age-adjusted incidence and temporal trends were calculated based on 1247 AITL patients from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER)-13 database. A total of 1525 AITL patients from the SEER-18 database and 43 patients from our single center were included for survival analysis and nomogram construction.

Results

The age-adjusted incidence for overall cohort was 0.123 [95% confidence interval (CI), 0.117–0.131) per 100 000 during 1992–2017. The overall incidence increased steeply at the rate of 15.3% (95%CI 11.0%–19.8%, P<0.001) per year during 1992–2004, but remained stable during 2004–2017 (P=0.200). Similar incidence trends were observed in age, sex, and stage subgroups. The final nomograms consisted of four variables: age at diagnosis, sex, Ann Arbor stage, and primary site. The concordance index (C-index) of the nomogram for 5-year overall survival prediction was 0.717, 0.690 and 0.820 in the training cohort, validation cohort-1 and cohort-2, respectively. Regarding the disease-specific survival (DSS), the nomogram also demonstrated a good discrimination level, with the C-index for predicting the probability of DSS at 5 years of 0.716, 0.682 and 0.813 for the three cohorts, respectively. The calibration displayed good concordance between the nomogram-predicted and actual observed outcomes.

Conclusion

The age-adjusted incidence for AITL was low during 1992–2017. The incidence continuously increased during 1992–2004, but remained stable during 2004–2017. The nomograms as proposed may provide a favorable and accurate prognostic survival prediction in AITL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol, 2002,13(1):140–149

    Article  CAS  Google Scholar 

  2. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol, 2008,26(25):4124–4130

    Article  Google Scholar 

  3. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood, 2006,107(1):265–276

    Article  CAS  Google Scholar 

  4. Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood, 2012,119(12):2837–2843

    Article  CAS  Google Scholar 

  5. Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol, 2013,31(2):240–246

    Article  CAS  Google Scholar 

  6. Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood, 2017, 129(9):1095–1102

    Article  CAS  Google Scholar 

  7. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood, 2008,111(9):4463–4470

    Article  CAS  Google Scholar 

  8. International Non-Hodgkin’s Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med, 1993,329(14):987–994

    Article  Google Scholar 

  9. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood, 2004,103(7):2474–2479

    Article  CAS  Google Scholar 

  10. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Databases. https://seer.cancer.gov/data-software/. Accessed 2021-12-01.

  11. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 1996,15(4):361–387

    Article  Google Scholar 

  12. Boren E, Gershwin ME. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev, 2004,3(5):401–406

    Article  CAS  Google Scholar 

  13. Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood, 1992,79(7):1789–1795

    Article  CAS  Google Scholar 

  14. de Leval L, Parrens M, Le Bras F, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica, 2015, 100(9): e361–364

    Article  Google Scholar 

  15. Hong H, Fang X, Huang H, et al. The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol, 2020,189(5):908–912

    Article  CAS  Google Scholar 

  16. Briski R, Feldman AL, Bailey NG, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J, 2014,4:e214

    Article  CAS  Google Scholar 

  17. Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol, 2014,25(11):2211–2217

    Article  CAS  Google Scholar 

  18. Xu B, Liu P. No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases. PLoS One, 2014,9(3):e92585

    Article  Google Scholar 

  19. d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol, 2012,30(25):3093–3099

    Article  Google Scholar 

  20. Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol, 2018,29(3):715–723

    Article  CAS  Google Scholar 

  21. Hong H, Fang X, Wang Z, et al. Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. Leuk Lymphoma, 2018,59(12):2911–2916

    Article  Google Scholar 

  22. Kameoka Y, Takahashi N, Itou S, et al. Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma. Int J Hematol, 2015,101(6):536–542

    Article  CAS  Google Scholar 

  23. Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet, 2014,46(4):371–375

    Article  CAS  Google Scholar 

  24. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet, 2014,46(2):171–175

    Article  CAS  Google Scholar 

  25. Nguyen PN, Tran NTB, Nguyen TPX, et al. Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis: RHOA mutations in AITL. Clin Lymphoma Myeloma Leuk, 2021,21(7):431–438

    Article  Google Scholar 

  26. Fukumoto K, Nguyen TB, Chiba S, et al. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. Cancer Sci, 2018,109(3):490–496

    Article  CAS  Google Scholar 

  27. Butzmann A, Sridhar K, Jangam D, et al. A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T-cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis. Int J Mol Med, 2020,46(4):1466–1476

    CAS  Google Scholar 

  28. Yang Y, Zhang YJ, Zhu Y, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia, 2015,29(7):1571–1577

    Article  CAS  Google Scholar 

  29. Han Y, Yang J, Liu P, et al. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Oncologist, 2019,24(11):e1251–e1261

    Article  Google Scholar 

  30. Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol, 2015,16(4):e173–180

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank all of the staff of the National Cancer Institute for their contribution to the SEER program. We also sincerely thank the patients, their families, and all the investigators for their contribution to this study.

Author information

Author notes

  1. The authors contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, China

    Hai-zhu Chen, Yun-xia Tao, Yu Zhou, Qiao-feng Zhong, Li-qiang Zhou & Yuan-kai Shi

Authors
  1. Hai-zhu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun-xia Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiao-feng Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li-qiang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuan-kai Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuan-kai Shi.

Ethics declarations

All authors declare no conflict of interest.

Additional information

This study was financially supported by the China National Major Project for New Drug Innovation (No. 2017ZX09304015) and Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) (No. 2016-I2M-1-001).

Supplementary data

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Hz., Tao, Yx., Zhou, Y. et al. Incidence, Survival Outcome, and Prognostic Nomogram of Patients with Angioimmunoblastic T-cell Lymphoma: a Population-based Analysis. CURR MED SCI 42, 1220–1230 (2022). https://doi.org/10.1007/s11596-022-2651-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-022-2651-z

Key words

Search

Navigation